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Clinical oncology relies increasingly on biomedical imaging, with anatomical imaging, 
especially using CT and 1H-MRI, forming the mainstay of patient assessment, from diagnosis 
to treatment monitoring. However, the need for further improvements in specificity and 
sensitivity, coupled with imaging techniques that are reaching their limit of clinically 
attainable spatial resolution, has resulted in the emergence and growing use of imaging 
techniques with additional functional read-outs, such as 18FDG-PET and multi-parametric 
MRI. These techniques add a new dimension to our understanding of the biological behavior 
of tumors, allowing a more personalized approach to patient management. 
 
An important functional imaging target in cancer is metabolism.  PET measurements of 
18Fluorodeoxyglucose uptake, a 18F labeled glucose analog, (18FDG-PET), and 1H-MRS 
measurements, have both been used to investigate tumor metabolism for diagnostic purposes. 
However, clinical applications of MRS have been hampered by low sensitivity and 
consequently low spatial and temporal resolution (Glunde and Bhujwalla, 2011). Nuclear 
spin hyperpolarization of 13C-labelled substrates, using dynamic nuclear polarization (DNP), 
which radically increases the sensitivity of these substrates to detection by 13C MRS 
(Ardenkjaer-Larsen et al., 2003), has created a renewed interest in MRS measurements of 
tissue metabolism. Successful translation of this technique to the clinic was achieved recently 
with measurements of  [1-13C]pyruvate metabolism in prostate cancer (Nelson et al., 2013) 
(see Figure 1). We explore here the potential clinical roles for metabolic imaging with 
hyperpolarized [1-13C]pyruvate. 
 
Dynamic nuclear polarization 
DNP, which can increase the signal-to-noise ratio in the solution-state 13C MR experiment by 
104 - 105 fold (Brindle et al., 2011) has enabled in vivo imaging of various metabolites and 
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their enzymatic conversion into other species, as well as metabolic fluxes in central metabolic 
pathways, such as glycolysis (Meier et al., 2011;Harris et al., 2013;Rodrigues et al., 2014) 
and the tricarboxylic acid cycle (Schroeder et al., 2009;Merritt et al., 2011;Chen et al., 2012). 
The principle limitation of the technique is the short half-life of the polarization; for [1-
13C]pyruvate in vivo this is typically between 30 – 40 s, which means that the hyperpolarized 
signal will last for 2 – 3 minutes. Therefore the substrate, whose metabolism is to be imaged, 
must be transferred promptly from the polarizer, injected intravenously and then transit 
quickly via the circulation to the tissue of interest, where it should be taken up and 
metabolized rapidly (Gallagher et al., 2011;Brindle, 2015). To date numerous molecules, in 
addition to 13C-labelled pyruvate, have been successfully hyperpolarized and their 
metabolism imaged, including [1,4-13C2]fumarate, as a marker of cell necrosis (Gallagher et 
al., 2009;Clatworthy et al., 2012); [U-2H, U-13C]glucose for assessment of glycolytic and 
pentose phosphate pathway activities and for detecting early treatment response (Rodrigues et 
al., 2014); 13C-labelled bicarbonate for in vivo mapping of pH (Gallagher et al., 2008a); and 
13C-labelled urea as a marker of perfusion (Wilson et al., 2010), amongst others (Day et al., 
2007;Gallagher et al., 2009;Wilson et al., 2010;Kurhanewicz et al., 2011). Despite initial 
interest in vascular imaging (Golman et al., 2002;Svensson et al., 2003;Mansson et al., 2006), 
the main focus has been on imaging metabolism in tumors (Chen et al., 2007;Day et al., 
2007;Gallagher et al., 2009) and cardiac tissue (Merritt et al., 2007;Golman et al., 
2008;Merritt et al., 2008;Schroeder et al., 2008;Dodd et al., 2014).  
 
Pyruvate 
Pyruvate is an important intermediate in many biochemical pathways (Denton and Halestrap, 
1979). As an end product of glycolysis, pyruvate can be reduced by NADH to generate 
lactate, in the readily reversible reaction catalyzed by lactate dehydrogenase, or 
Prov
io al
 4 
transaminated by glutamate, in the reversible reaction catalyzed by alanine aminotransferase 
(ALT), to form alanine. In tissues with high levels of mitochondrial activity, such as heart 
muscle, pyruvate may be irreversibly decarboxylated to form carbon dioxide in the reaction 
catalyzed by the mitochondrial pyruvate dehydrogenase (PDH) complex (Schroeder et al., 
2008). Since increased aerobic glycolysis is a well-recognized hallmark of cancer (Gatenby 
and Gillies, 2004;Hanahan and Weinberg, 2011) this has made it an attractive pathway to 
probe for diagnostic and treatment monitoring purposes (Golman et al., 2006;Day et al., 
2007;Nelson et al., 2013). 
 
Potential clinical roles 
Preclinical studies have demonstrated that hyperpolarized [1-13C]pyruvate is a promising 
probe for oncological imaging, with increased lactate labeling observed in tumors as 
compared to normal tissues (Golman et al., 2006;Park et al., 2010). The substrate has the 
potential to be used in many steps of patient management. A recent study demonstrated the 
potential of hyperpolarized [1-13C]pyruvate as an imaging biomarker for early detection and 
secondary screening of pancreatic cancer, where a decrease in the hyperpolarized [1-
13C]alanine/[1-13C]lactate ratio was observed in the progression from precursor lesions to 
adenocarcinoma (Serrao et al., 2015). In another study, [1-13C]pyruvate detected metabolic 
changes prior to tumor formation (Hu et al., 2011). Additionally, in the first reported clinical 
trial in prostate cancer, increased lactate labeling was observed in histologically confirmed 
areas of disease that were not identifiable by conventional 1H-MRI measurements (Nelson et 
al., 2013) (Figure 1). The few studies that have explored the role of [1-13C]pyruvate in 
grading and prognosis, which were in the transgenic mouse model of prostate 
adenocarcinoma (TRAMP), have also produced promising results (Albers et al., 2008;Chen 
AP, 2008).  Tumor grading by biopsy can sometimes be difficult depending on the 
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accessibility of the organ of interest. Translation of the DNP technique to the clinic may 
allow more accurate targeting of biopsy procedures. Since lactate labeling is increased in 
regions of hypoxia the technique also has the potential to be used for treatment planning in 
radiotherapy (Krishna et al., 2013;Bluff et al., 2015).  Clinical assessments of tumor 
responses to treatment are still based largely on observed changes in tumor size (Eisenhauer 
et al., 2009). However, this might not always be appropriate, particularly for detection of 
early responses or if the drug does not result in tumor shrinkage, for example in the case of 
anti-angiogenic drugs (Brindle, 2008;Bohndiek et al., 2012). Additionally, treatment 
assessment using 18FDG-PET is difficult in some organs, e.g. prostate and brain, due to both 
low tumor uptake and increased background uptake respectively (Brindle, 2008). Evaluation 
of treatment response is likely to be the clinical scenario where hyperpolarized [1-
13C]pyruvate will have the most impact, as it could lead to immediate changes in clinical 
management, allowing the clinician to change a non-responding patient to a more effective 
drug at an early stage (Brindle, 2008). Early assessment of treatment response could also be 
used to accelerate the introduction of new drugs into the clinic by providing an indication of 
drug efficacy in early stage clinical trials.  In support of this are numerous studies showing 
early decreases in hyperpolarized 13C label exchange between injected [1-13C]pyruvate and 
the endogenous lactate pool in a range of cancer models following treatment with cytotoxic 
chemotherapy (Day et al., 2007;Witney et al., 2010), targeted drugs (Bohndiek et al., 
2010;Dafni et al., 2010;Ward et al., 2010), and radiotherapy (Day et al., 2011;Bohndiek et al., 
2012;Saito et al., 2015).  
There is as yet no direct evidence to support the suggestion that residual disease/recurrence 
can be identified by increased lactate labeling. However, observations of increased lactate 
labeling in areas of disease and following disease progression (Nelson et al., 2013;Serrao et 
al., 2015) make this likely.  There is, however, evidence that hyperpolarized [1-13C]pyruvate 
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can be used to assess normal tissue toxicity, with an increase in the [1-13C]lactate/[1-
13C]pyruvate ratio occurring in radiation-induced lung injury (Thind et al., 2013;Thind et al., 
2014). 
 
Advantages of metabolic imaging with [1-13C]pyruvate 
Advantages compared to 18FDG-PET 
Metabolic imaging of cancer in the clinic has principally been with 18FDG-PET, which has 
been used to stage tumors and to assess treatment response. Despite its high sensitivity and 
capability to provide whole-body images the use of ionizing radiation is a drawback, limiting 
its application in children and women of reproductive age, and when multiple investigations 
are needed, for example as might be required for guiding treatment in an individual patient.  
A similar clinical role can be envisaged for [1-13C]pyruvate as has been established for 
18FDG-PET. Both techniques can be used to detect increased glycolytic flux (Menzel et al., 
2013) and have been shown to be comparably sensitive in detecting tumor response to 
treatment (Witney et al., 2009). However, since hyperpolarized [1-13C]pyruvate effectively 
detects lactate accumulation (Gallagher et al., 2011), a defining feature of cancer metabolism, 
i.e. the failure to oxidize pyruvate in the presence of oxygen and reduce it instead to lactate 
(the “Warburg Effect”), this means that hyperpolarized [1-13C]pyruvate may be more specific 
for detecting cancer than 18FDG-PET. The latter detects only elevated levels of glucose 
uptake, which is a feature of many normal tissues as well as cancer, for example the brain.  
The specificity of cancer detection by hyperpolarized [1-13C]pyruvate may be confounded, 
however, by the presence of hypoxia, which will also lead to lactate accumulation and 
increased lactate labeling (Bluff et al.). Another drawback of imaging with hyperpolarized [1-
13C]pyruvate is that the short half-life of the polarization precludes whole-body imaging. 
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Advantages compared to 1H MRS 
1H-MR spectroscopy and spectroscopic imaging measurements of tissue metabolite profiles 
are label free and have found some applications, for example in identifying different types of 
brain tumor (Horska and Barker, 2010). A notable example is the detection of 2-
hydroxyglutarate, which can be used to identify glioblastomas with isocitrate dehydrogenase 
mutations (IDH) (Choi et al., 2012). 1H MRSI has also proved to be important in the prostate, 
where it can improve the specificity of detection and determination of tumor extent when 
combined with other MR imaging sequences (Johnson et al., 2014). However, detectable 
metabolites are present in only millimolar concentrations, as compared to tissue water 
protons, which are present at ~80 M, which results in long data acquisition times and limited 
spatial resolution.  In addition data processing can be more complex and the biochemical 
information provided may be unfamiliar to many clinicians, which has limited routine clinical 
application. Moreover, 1H MR spectroscopy and spectroscopic images of metabolite profiles 
provide a static picture of tumor metabolism. Imaging with hyperpolarized 13C-labeled 
substrates, on the other hand, provides dynamic metabolic flux information in the form of 
images that can be acquired at relatively high spatial and temporal resolutions and therefore 
should provide an improved assessment of tumor behavior. Additionally co-injection of 
different hyperpolarized substrates could also provide additional functional information in the 
same acquisition, e.g. pyruvate for assessing glycolytic activity and urea for assessing tumor 
perfusion (von Morze et al., 2012). 
 
Combining metabolic imaging with hyperpolarized [1-13C]pyruvate with new 
technologies 
PET-MRI 
This is an emerging combined imaging modality with significant potential for clinical 
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assessment of cancer patients (Rosenkrantz et al., 2015). Simultaneous PET-MR 
measurements with hyperpolarized 13C and 18F labeled substrates would allow a multi-
parametric assessment of the primary lesion and its metastases in a single imaging session, 
which potentially could be used to identify imaging-based phenotypes that have prognostic 
value and which may give a more specific readout of treatment response.  For example, PET 
measurements of 18FDG uptake assess just the first three steps in tumor glucose metabolism, 
that is delivery via the bloodstream, uptake on the glucose transporters and phosphorylation 
and trapping in the reaction catalyzed by hexokinase. 13C MRSI measurements of the 
exchange of hyperpolarized 13C label between injected [1-13C]pyruvate and the endogenous 
lactate pool again assess delivery via the bloodstream and effectively the last two steps in the 
glycolytic pathway, that is the steps catalyzed by lactate dehydrogenase and the plasma 
membrane monocarboxylate transporters. Therefore by combining 18FDG-PET and 
hyperpolarized [1-13C]pyruvate measurements we may be able to assess flux in the entire 
glycolytic pathway, for example increased mitochondrial oxidation of pyruvate may have no 
effect on 18FDG uptake but could decrease 13C labeling of lactate. There are other PET 
probes of tumour metabolism that could also be used alongside hyperpolarized [1-
13C]pyruvate, and which could provide complementary information. These include 11C-
acetate, as a marker of fatty acid synthesis, and labelled glutamine, which can be used to 
assess glutaminolysis; both of which are up-regulated in tumour cells (Hensley et al., 2013) 
(Hosios and Vander Heiden, 2014). These PET probes may be especially useful in tumours 
where 18FDG is ineffective, e.g. in prostate tumours (Grassi et al., 2012) and in gliomas 
(Venneti et al., 2015), and where the corresponding hyperpolarized 13C-labelled probes are 
limited. For example the metabolism of hyperpolarized [1-13C]acetate has been detected in 
vivo (Bastiaansen et al., 2013), however the short lifetime of the hyperpolarization means that 
it could not be used to monitor fatty acid synthesis, where PET studies with [1-11C]acetate in  
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animal tumour models have shown that it can take over 60 minutes before there is substantial 
incorporation into the fatty acid pool (Lewis et al., 2014). In the case of [5-13C]glutamine a 
relatively short hyperpolarization lifetime and slow metabolism (Gallagher et al., 2008b) has 
precluded imaging in vivo (Cabella et al., 2013). 
 
Liquid biopsies 
Blood and urine biomarkers, obtained from “liquid biopsies”, are also evolving, providing 
information in a non-invasive way allied to the advantages of collection simplicity and 
relatively low cost. Many body fluid biomarkers have been reported for different types of 
cancer however few have become established in the clinic, usually because they lack 
specificity. A recent promising example is a panel of three urine biomarkers for early 
detection of pancreatic cancer (Radon et al., 2015).  Rapid advances in DNA sequencing 
technology have allowed somatic mutations present in tumor cells to be detected and tracked 
in blood-borne circulating tumor DNA (ctDNA). These fragments of DNA, which have been 
detected with most types of cancer, have been demonstrated to have potential roles in early 
detection, staging, and in detecting response to therapy and acquired resistance to treatment 
(Murtaza et al., 2013;Bettegowda et al., 2014).  Although measurements with hyperpolarized 
13C-labelled cell substrates and these new circulating biomarkers are still their infancy it 
seems likely that they will provide complementary information, for example in the 
assessment of tumor heterogeneity. 
 
Conclusion and Future Directions 
Imaging with hyperpolarized 13C-labelled cell substrates has the potential to become a 
powerful tool in many steps of clinical evaluation, allowing a more personalized approach to 
treatment. The first clinical trial established the feasibility of imaging human tumors with 
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hyperpolarized [1-13C]pyruvate. Since this substrate can be used to assess glycolysis, which 
is up regulated in many tumors, then this should make it a very general tool for oncological 
imaging in the clinic. Despite the biological insights that imaging with hyperpolarized 13C-
labelled substrates promises to deliver in the clinic, it will nevertheless have to prove itself 
against established and emerging clinical techniques, demonstrating that it can provide 
unique information that changes clinical practice. 
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Figure 1 – Imaging prostate cancer with hyperpolarized [1-13C]pyruvate. The T2-weighted 
image of a patient with biopsy-proven bilateral prostate cancer showed only a unilateral 
decrease in signal intensity.  However, the metabolic image ([1-13C]lactate/[1-13C]pyruvate 
ratio) detected disease on both the right and left sides of the prostate. Reproduced from 
(Nelson et al., 2013) with permission. 
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